The science behind albumin engineering to improve drug efficacy and tolerability
Developers of many peptide and protein drugs frequently face PK and PD challenges that can limit the effectiveness of their drugs due to clearance from the circulatory system. Resolution of these issues can require frequent and/or high dose levels to succeed in the development process. Both frequent dosing and high dose levels can be detrimental to patient compliance and acceptance as well possible negative side effects/dangers associated with high dosing.
By overcoming these problems and improving patient compliance rates, many drug companies have been able to increase market share and also patent new products. Ultimately leading to increased revenue and drug products that can become market leaders and establish the drugs producer as having a highly patient centric ethos and improving their corporate image in an industry often viewed unfavourably by the public.
During this webinar you will learn how Novozymes and its partners have harnessed the power of albumin to overcome many of these challenges to develop a technology to optimise dose frequency and quantity using the properties of the body's natural plasma transporter protein.
Veltis® is a clinically-proven technology based on engineered albumins to allow the drug developer to optimise dose size and frequency to achieve stricter patient adherence (compliance) for improved therapeutic impact by targeting once weekly, once two-weekly, or once monthly dosing. The technology is delivered by Novozymes Biopharma and is provided with access to our extensive technical and regulatory support as well as to partner providers. It is well-established by our customers in a variety of indications including diabetes, haemophilia and neutropenia.
To learn more about the science behind this technology and how to get access to it, sign up for this webinar.
Presented by
Dr Darrell Sleep,
Director, Biopharma R&D
Sleep has nearly 30 years of experience in Biopharma discovery and development. His team has developed processes for the production of recombinant human albumin, albumin fusions, bioengineered albumins, transferrin and antibody fragments. Current research is directed at controlling the half-life of peptides and proteins through engineered albumins with modulated affinity for the neonatal Fc receptor.
Dermot Pearson,
Strategic Marketing Director
Dermot Pearson is Strategic Marketing Director with responsibility for market development of our albumins in drug formulation, half-life extension and targeting. His roles include overseeing product market development, branding, and pricing, and life cycle management, all on global basis. A member of business unit management team and in the past has held roles in R&D, Quality and GMP Product Manufacturing.
